Low doses of high-potency antithymocyte globulin (ATG) in severe aplastic anemia: experience with the Mexican ATG

Acta Haematologica
J L Delgado-LamasM Elena Zarzosa

Abstract

Twenty patients with severe aplastic anemia (SAA) were treated with low doses (1-5 mg/kg/day) of a high-potency antithymocyte globulin (ATG) produced in Mexico, shown to have at least a 10-fold potency as compared with other globulins of commercial sources. Patients received ATG within a 10-day period, every other day (5 doses) at a dose of 1 mg/kg/day (4 courses), 2 mg/kg/day (12 courses) or 5 mg/kg/day (8 courses). Four patients received 2 consecutive courses of different doses of ATG. A response rate of 42% was recorded in the group, assessed by means of increases in reticulocytes, granulocytes or platelets. One patient showed a complete remission. The 570-day survival of the group was 51%. It is concluded that the domestically produced ATG is useful in the treatment of some patients with SAA in Mexico.

Citations

Feb 7, 2012·Archivum Immunologiae Et Therapiae Experimentalis·David Gómez-AlmaguerGuillermo J Ruiz-Arguelles
Oct 1, 1995·British Journal of Haematology·A J WinterE L Jones
Jun 1, 1992·Pediatric Dermatology·A L BittencourtB Schnitzer
Jun 7, 2005·Expert Opinion on Biological Therapy·Jose C Jaime-PerezDavid Gomez-Almaguer

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

© 2022 Meta ULC. All rights reserved